Japan set up pharmaceutical manufacturers using iPS cells
-
Last Update: 2014-03-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: bioprospecting on March 6, 2014, Sumitomo Pharmaceutical Co., Ltd of Japan announced that it had set up a pharmaceutical manufacturer in Hong Kong Island, Central District of Kobe City at the end of February this year, and would devote itself to the treatment of ophthalmopathy with induced pluripotent stem cells (iPS cells) Helios, a venture identified by the Institute of physics and Chemistry (RIKEN), also contributes half of the investment, and the two companies will carry out joint research Sumitomo Japan and Helios are developing a drug for the treatment of age-related macular degeneration (AMD) eye disease, which is planned to be put into practical use in 2018 The name of the new company is "vision", which means vision regeneration The registered capital is 50 million yen (about 3 million yuan).
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
